A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), with recent evaluations showing a decrease in the average 12-month price target from $170 to $164.5. The company's financials reveal a strong net margin and ROA, but challenges in ROE and revenue growth compared to peers.
September 09, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Jazz Pharmaceuticals has received mixed analyst ratings, with a decrease in the average price target to $164.5. The company shows strong net margins and ROA but faces challenges in ROE and revenue growth compared to peers.
The mixed analyst ratings and lowered price target suggest a neutral short-term impact on JAZZ's stock price. While the company has strong net margins and ROA, its challenges in ROE and revenue growth compared to peers may offset positive sentiments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100